Nanoform's proprietary bionanoparticle technology can deliver large-molecule drug particles as small as 50 nm while retaining biological activity. This can not only enable more patient-friendly approaches to drug delivery, but also potentially higher loads of active ingredients.
Our technology has been developed with the goal of allowing more life-changing large-molecule drugs to reach the market. With it, pharmaceutical developers can potentially:
Enhance drug loading capacity in formulations
Tailor release profiles
Enable novel delivery routes
Engineer new drug combinations
Implement lighter infrastructures for drug logistics
The technology has already been leveraged to nanoform monoclonal antibodies, achieving a narrow particle size distribution without compromising structural integrity. It has also shown co-processing capabilities with large molecules alongside other APIs or excipients.
Learn more about how our bionanoparticle technology can help your large-molecule drugs reach their full therapeutic potential.